Genmab — November 2023
-
FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous
-
https://firstwordpharma.com/story/5804477?from=article For Genmab er det Carvykti der er interessant. Er af JNJ slået op til noget stort i myeloma - dara konkurrent. Så dette er meget vigtig for Genmab.
-
-
@Stockbull: Hvis Mag7 tages ud af S&P500 + inflation tages i betragtning er faldet måske allerede sket?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind